These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 20170372)
1. HIV neutralizing antibodies: clinical correlates and implications for vaccines. Doria-Rose NA J Infect Dis; 2010 Apr; 201(7):981-3. PubMed ID: 20170372 [No Abstract] [Full Text] [Related]
2. HIV Vaccines: One Step Closer. Low MSY; Tarlinton D Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424 [TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Kwong PD; Mascola JR; Nabel GJ Nat Rev Immunol; 2013 Sep; 13(9):693-701. PubMed ID: 23969737 [TBL] [Abstract][Full Text] [Related]
4. HIV vaccine development--improving on natural immunity. Johnston MI; Fauci AS N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447 [No Abstract] [Full Text] [Related]
5. Tiny steps towards an HIV vaccine. Willyard C Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706 [No Abstract] [Full Text] [Related]
6. Cure of HIV infection: is the long wait over? Shearer WT J Allergy Clin Immunol; 2014 Jul; 134(1):20-2. PubMed ID: 25117800 [No Abstract] [Full Text] [Related]
7. The potential of broadly neutralizing antibodies for HIV prevention. Gelderblom HC; Corey L; Barouch DH J Int AIDS Soc; 2024 May; 27(5):e26257. PubMed ID: 38757844 [No Abstract] [Full Text] [Related]
8. A vaccine strategy for inducing broadly neutralizing antibodies against HIV. Marchal I Nat Biotechnol; 2024 Jun; 42(6):847. PubMed ID: 38886609 [No Abstract] [Full Text] [Related]
9. Germinal Center Lymphocyte Ratios and Successful HIV Vaccines. Gonzalez-Figueroa P; Roco JA; Vinuesa CG Trends Mol Med; 2017 Feb; 23(2):95-97. PubMed ID: 28089302 [TBL] [Abstract][Full Text] [Related]
10. New mouse models provide insights into how to design a more effective HIV vaccine. Harper KN AIDS; 2017 Jan; 31(3):N3-N4. PubMed ID: 28002067 [No Abstract] [Full Text] [Related]
11. In vivo protection by broadly neutralizing HIV antibodies. van Gils MJ; Sanders RW Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020 [TBL] [Abstract][Full Text] [Related]
13. Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Moore PL; Williamson C; Morris L Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881 [TBL] [Abstract][Full Text] [Related]
14. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028 [TBL] [Abstract][Full Text] [Related]
16. Progress in the rational design of an AIDS vaccine. Nabel GJ; Kwong PD; Mascola JR Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2759-65. PubMed ID: 21893538 [TBL] [Abstract][Full Text] [Related]
17. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Montefiori DC; Mascola JR Curr Opin HIV AIDS; 2009 Sep; 4(5):347-51. PubMed ID: 20048696 [TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Burton DR; Poignard P; Stanfield RL; Wilson IA Science; 2012 Jul; 337(6091):183-6. PubMed ID: 22798606 [TBL] [Abstract][Full Text] [Related]
19. Moving the HIV vaccine field forward: concepts of protective immunity. Kent SJ; Davenport MP Lancet HIV; 2019 Jun; 6(6):e406-e410. PubMed ID: 31080107 [TBL] [Abstract][Full Text] [Related]
20. HIV. The modern era of HIV-1 vaccine development. Mascola JR Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931 [No Abstract] [Full Text] [Related] [Next] [New Search]